AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything

Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics significantly lowered cardiovascular risk in a large population without previous events (primary prevention). However, it presented an intermediate risk of cardiovascular disease onset.

The TIPS-3 (The International Polycap Study 3) study had a 2-by-2-by-2 factorial design, and was partly presented at the American Heart Association (AHA) 2020 Congress.

Adding 75 mg of aspirin to the poypill diminished the relative risk of the study’s primary endpoint (a composite of death, infarction, stroke, sudden death, heart failure, or revascularization) by 31% compared to a double placebo. In absolute terms, this reduction is equal to 1.7%.

The polypill (without aspirin added) showed a borderline statistically significant benefit compared with a placebo. After 5 years of follow-up, the primary endpoint was reached in 4.4% of the polypill arm vs. 5.5% of the placebo arm (hazard ratio: 0.79; 95% confidence interval: 0.63-1.00).

The polypill included 40 mg of simvastatin, 100 mg of atenolol, 10 mg of ramipril, and 25 mg of hydrochlorothiazide.


Read also: The Most Read Scientific Articles in Interventional Cardiology.


Not all physicians were sold on this idea. Many considered the simvastatin dose as excessive, given its possible subsequent pharmacological interactions. The same consideration was applied, even more, to the 100 mg of atenolol in patients with no-known heart disease. 

Polypill

Original Title: Polypill with or without aspirin in persons without cardiovascular disease.

Reference: Yusuf S et al. Presentado en el congreso AHA 2020 y publicado simultánemante en N Engl J Med 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...